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Development of Extragenital Lichen
Sclerosus in Malignant Melanoma
Patients Treated With Ipilimumab in
Combination With Nivolumab
S. Morteza Seyed Jafari* , Laurence Feldmeyer and Robert E. Hunger
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
The immune checkpoint inhibitors opened a new era for the treatment of melanoma.
Nowadays, combined immune checkpoint inhibitors are administered to provide additive
or synergistic effects on anti-melanoma immunity. The use of these drugs comes
with serious adverse events related to excessive immune activation. Here, we present
development of extragenital lichen sclerosus in a patient with metastatic malignant
melanoma, during the combined therapy with checkpoint inhibitors.
Keywords: checkpoint inhibitors, extragenital lichen sclerosus et atrophicus, ipilimumab, malignant melanoma,
metastatic, nivolumab
INTRODUCTION
The immune checkpoint inhibitors opened a new era for the treatment of melanoma (1). As potent
immune checkpoint inhibitors, antibodies against cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) and programmed cell death protein 1 (PD-1) are currently in clinical use worldwide
(1). Ipilimumab, a human IgG1 monoclonal antibody, blocks CTLA-4 (1). Nivolumab, a fully
human IgG4 anti-PD-1 antibody, blocks selectively the interaction of PD-1 and PD-L1/PD-L2
(1). Nowadays, combined immune checkpoint inhibitors are administered to provide additive or
synergistic effects on anti-melanoma immunity (1). The use of these drugs comes with serious
adverse events related to excessive immune activation, collectively known as immune-related
adverse events, such as colitis, hepatitis, thyroiditis, lichenoid dermatoses, bullous dermatoses,
psoriasis, and morphea (2, 3). The recent papers by Wernham et al. (3) and di Meo et al.
(2) described an association between nivolumab treatment and genital and extragenital lichen
sclerosus, respectively. However, there are no cases in the literature on the association between
combined immune checkpoint inhibitors and extragenital lichen sclerosus. Here, we present
development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma,
during the combined therapy with checkpoint inhibitors.
REPORT OF THE CASES
A primary melanoma with 0.6-mm Breslow depth and without ulceration was detected on the
back of a 39-year-old female patient. Thereafter, the patient underwent regular clinical follow-up.
Six years later, during a routine control, metastatic lesions in the brain and lung were diagnosed.
Therefore, a combined therapy with ipilimumab and nivolumab was initially started and followed
by monotherapy with nivolumab, as discussed before (4). The therapy was stopped after 2 years
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FIGURE 1 | Clinical image shows an atrophic, indurated, and hypopigmented plaque on left submammary region. Histologically, extragenital lichen sclerosus is
characterized by hyperkeratosis (+), epidermal atrophy with flattening of rete ridges (*), edema in the superficial dermis (#), and homogenized collagen in the dermis
with subtotal loss of skin adnexal structures (**).
with acceptable clinical response. However, during the last
months of the therapy, she presented with an itchy atrophic,
indurated hypopigmented plaque on left submammary region
(Figure 1). The clinical suspicion of extragenital lichen sclerosus
was confirmed by histological evaluation of the lesion revealing
hyperkeratosis, epidermal atrophy with flattening of rete
ridges, edema in the superficial dermis, and homogenized
collagen in the dermis with subtotal loss of skin adnexal
structures (Figure 1). Therefore, a local therapy with clobetasol
propionate 0.05% cream was initiated. After 2 weeks of daily
application, the therapy was reduced to twice weekly, and a
daily therapy with tacrolimus ointment 0.1% was added. This
combination therapy significantly improved the patients’ itch and
induration of the plaque.
DISCUSSION
To our knowledge, our case is the first report of an association
between extragenital lichen sclerosus during the combined
therapy with checkpoint inhibitors. Similar to the cases
reported by Wernham et al. (3) and di Meo et al. (2),
our patient presented with an itchy atrophic, indurated
hypopigmented plaque during the therapy. The etiology of
lichen sclerosus, a chronic inflammatory connective tissue
disorder, has not been fully elucidated (3, 5–7). However,
the increased prevalence of organ-specific autoantibodies
in lichen sclerosus, such as extracellular matrix protein 1,
supports that the autoimmune mechanisms might play a
pathogenetic role (5, 6, 8). In addition, increased levels
of Th1-specific cytokines, dense T-cell infiltrates, and
enhanced BIC/miR-155 expression has been found (2, 3,
7). This might explain an association of lichen sclerosus
with checkpoint inhibitor therapy. As ipilimumab increases
activated T cells and enhances humoral immunity and
nivolumab prevents the deactivation of T lymphocytes, thus
promoting self-reactive T cells (2, 9), both drugs might lead
to autoimmune diseases, such as lichen sclerosus, as reported
before (2, 3).
In conclusion, extragenital lichen sclerosus should be
considered as one of the immune-related adverse events of
combined therapy with checkpoint inhibitors. Local therapy
with corticosteroids and/or calcineurin inhibitors could reduce
the patients’ discomfort and avoid disease progression. Despite
presence of strong clinical and histological clues in the
patients, occurrence of extragenital lichen sclerosus irrelevant
to the immune therapy could not be excluded. Therefore,
further studies might be demanded to investigate this issue
in more details.
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